Delisting risk is removed in the near term, but the heavy dilution from the capital raises will pressure the stock. Monitor upcoming quarterly filings for cash burn rate and progress on Ampligen clinical trials. The removal of the .BC indicator may attract some buyers, but the company's fundamentals remain challenged.
Price Chart
Executive Summary
AIM ImmunoTech received formal notice from NYSE American that it has regained compliance with continued listing standards, resolving stockholders' equity deficiencies. The company raised approximately $8.5 million through warrant exercises and private placements in May and June 2026 to boost equity above the $6.0 million minimum. The '.BC' indicator will be removed from its ticker, eliminating immediate delisting risk.
Key Facts
- NYSE American confirmed AIM has regained compliance with Sections 1003(a)(i), (ii), and (iii) of the Company Guide.
- The '.BC' (below compliance) indicator will be removed from AIM's trading symbol.
- Company raised ~$3.5M from warrant exercise inducement on May 7, 2026.
- Company raised ~$2.4M from issuance of 7,519,351 shares and Class I warrants on May 21, 2026.
- Company raised ~$2.6M from issuance of 2,554,119 shares, 771,503 shares, pre-funded warrants, and Class J warrants on June 10, 2026.
- Aggregate gross proceeds from these transactions were approximately $8.5 million.
- Company believes stockholders' equity now exceeds the $6.0 million minimum requirement.
Financial Impact
Approximately $8.5 million in gross proceeds raised through dilutive equity and warrant issuances to meet the $6.0 million equity minimum. Significant dilution: over 10 million shares issued plus warrants for up to ~27 million additional shares.
Risk Factors
- Continued need for additional capital to fund operations and clinical trials.
- Potential future non-compliance if equity falls below $6.0 million again.
- Significant dilution from warrants (up to ~27 million shares) could pressure the stock.
- Clinical and regulatory risks for lead product Ampligen.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028615 |
| Exhibit: ex99-1.htm | 0001493152-26-028615 |
| Document: 0001493152-26-028615-index-headers.html | 0001493152-26-028615 |
| Document: 0001493152-26-028615-index.html | 0001493152-26-028615 |
| Document: 0001493152-26-028615.txt | 0001493152-26-028615 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers